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A-V fistulas in children (abst) 233
Abdominal pressure, CAPD (abst) 248
ACE inhibition
(abst) 212
captopril, inhibition (abst) 333
mechanisms in congestive heart failure 1390
Acetaminophen, nephropathy (abst) 192
Acetate
HCO3 transport (abst) 408
metabolism, bicarbonate generation during HD 1194
to bicarbonate dialysis (abst) 227
Acetazolamide
on NaJHCO3 cotransport (abst) 416
proteinuria (abst) 210
renal metabolism and ammoniagenesis 1279
Acid
CyA stimulates (abst) 414
dietary, effect on Mg (abst) 362
organic in Cl (abst) 439
phosphonoformic, mechanism of (abst) 359
Acid-base fluxes, determination (abst) 406
Acidic compartments in OMCD (abst) 417
Acidification
acute hypocapnia (abst) 405
glucagon inhibits urinary (abst) 407
intercalated cells of OMCD 1080
renal insufficiency (abst) 411
urine anion gap in evaluation (abst) 202
Acidosis
abnormal branched-chain amino acid metabolism
(abst) 386
alkalosis, respiratory, regulate ketoacid production
(abst) 410
chronic metabolic, increases glutamine transport
(abst) 399
cytoprotection (abst) 375
glucocorticoids and glutamine production in (abst) .... 410
glucocorticoids on glutamine utilization (abst) 417
H ATPase (abst) 407
hyperkalemia in hyperchloremic (abst) 209
insulin resistance in uremia (abst) 389
Na/H antiporter, NaHCO3 cotransporter (abst) 404
pH gradient across CCD 930
recovery of cell pH from respiratory (abst) 409
TAL and internephron heterogeneity to urine
concentration 549
Acquired renal cystic disease (abst) 210
Acute hypocapnia (abst) 405
Acute renal failure
acquire resistance to 1233
dietary protein (abst) 363
disposition of insulin (abst) 395
furosemide, renal blood flow (abst) 368
glycerol-induced, prostaglandin (abst) 378
hemorrhagic reduction in BP 725
human alpha 2b interferon (abst) 207
iron in ischemic and hemoglobinuric (abst) 373
ischemi, Ca and endothelium derived relaxing factor
(abst) 374
K loading, uranyl nitrate (abst) 376
nifedipine (abst) 865
open heart surgery (abst) 195
serum iron (abst) 865
Acute serum sickness
PAF mediates nephrotoxic nephritis 1248
Acute tubular necrosis
ACE inhibition S-143
furosemide no protection against ischemic (abst) 373
Adenine nucleotide concentration (abst) 396
nucleotide toxicity (abst) 374
Adenosine
modulates medullary injury (abst) 367
nucleotide, ATP (abst) 397
prostaglandin mediates 2-chioroadenosine (abst) 423
receptor regulation of erythropoietin secretion
(abst) 290
receptors (DPX) (abst) 265
signal transduction, Ca (abst) 259
Adenosine triphosphate
acidosis (abst) 407
adriamycin nephrosis, proteinuria 704
exogenous (abst) 402
sensitivity of K channels (abst) 436
Adenylate cyclase
activity, dietary protein (abst) 430
multi-hormonal control 512
ADH
PMA increase immunolabelling of toad bladder
(abst) 174
proteins, permeability response to (abst) 169
Adrenergic agonists, Ca (abst) 284
Adrenergic receptor
stimulation mechanism (abst) 160
Adrenoceptor, beta, in sheep (abst) 175
Adriamycin nephrosis
ATPase activity independent of proteinuria 704
protein restriction and CEI (abst) 1043
proteinuria (abst) 393
Adsorbent, carbonaceous in CRF (abst) 216
Adult respiratory distress syndrome
Cya associated (abst) 464
Afferent arteriole
distribution of renin and angiotensin S-4
Age
PTH action on Na-Ca exchange (abst)
related, P reabsorption (abst)
transplant outcomes in (abst)
transplantation in (abst)
water excretion (abst)
Aggrephore, vesicular traffic (abst)
Agonist, dopamine SKF 38393 (abst)
AIDS
xxxix
associated nephropathy (abst) 199
HTLVIII associated nephropathy (abst) 336
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kidney transplantation (abst) 456
related glomerulopathy 1167
related glomerulopathy (abst) 213
tubular nephropathy (abst) 195
ultrastructural markers (abst) 335
AIgM.Clq probe for C1qR (abst) 330
Albumin
glomerulopathy (abst) 315
hyperlipemia in nephrotic patients 1367
isoelectric point, nephrosis (abst) 321
Albuminuria
BP, hydrala (abst) 395
granulocytes (abst) 1043
Aldosterone
a-subunit of Na!K-ATPase in CCD 1104
ANP inhibits secretion (abst) 260
apical K-H exchange in colon (abst) 279Ba + effects on apical cation selectivity (abst) 442
chronic chloride depletion metabolic alkalosis
(abst) 417
cortical collecting cell monolayers (abst) 160
deficiency, papillary acidification parameters
(abst) 407
induced proteins, localization to luminal surface (abst) . 183
K concentration (abst) 279
kallikrein, kininogen and kinin, changing salt and
water 836
Alkali
picomole analysis of metals 1225
Alkalinization
IGF II induced (abst) 169
luminal and basolateral transport (abst) 415
Alkalosis
chloride depletion metabolic, aldosterone (abst) 417
chronic metabolic, acidification in PCT (abst) 412
citrate reabsorption (abst) 444
furosemide infusion (abst) 208
metabolic, sodium chloride determines severity 1355
new syndrome, lactic (abst) 191
Alkyldihydroxyacetone phosphate (abst) 293
Allergy, idiopathic nephrotic syndrome
(abst) 1415
Allograft
blood pressure in donor, recipient 1382
Allotypes in IMN 130
Alpha 2 adrenoceptor
agonist, VP (abst) 270
CEI S-l9l
characterization in arterioles (abst) 422
receptors (abst) 178
Alport syndrome, X-linked (abst) 1044
Aluminum
absorption (abst)
antacid in dialysis (abst)
collagen synthesis (abst) 342
deferoxamine in bone disease 1343
deferoxamine infusion test, neuropsychologic
(abst) 219
desferioxamine test (abst) 345





microcytic anemia in hemodialysis (abst) 225
neutron activation analysis (abst) 205
osteodystrophy, PTH 842
plasma levels in hemodialysis (abst) 229
PTH response to 15
removal is associated with vitamin D (abst) 346
subcellular localization in parathyroid glands
(abst) 344
transfer during HD (abst) 243
vitamin D 3 (abst) 352
Amdinocillin, urinary kinetics (abst) 196
Amiloride
and analogues of retard MDCK cyst growth (abst) . . . . 184
bicarbonate handling (abst) 418
medullary collecting duct 1121
Na influx (abst) 178
Na transport (abst) 301
resistance, LLC-PK1 (abst) 168
Amines, monensin, nigericin (abst) 287
Amino acid
ANP in dehydrated rats 760
hyperalimentation (abst) 220
induced hyperfiltration (abst) 418
infusion, hemodynamics (abst) 427
infusions, low sodium diet 992
oral, GFR (abst) 382







renal osteodystrophy (abst) 349
Aminonucleoside nephrosis
acute tubulointerstitial nephritis (abst) 317
status of glomerular proteoglycan 1298
Amlodipine monotherapy (abst) 295
Ammonia
determinants of entry along PCT (abst) 416
disequilibrium pH (abst) 416
secretion by tubule monolayers (abst) 405
Ammoniagenesis
ACZ on renal metabolism 1279
pathways and regulation (abst) 400
pH, l5N labelled glutamine and glutamate (abst) 400
phorbol esters (abst) 396
Amphotericin B, vasoconstriction (abst) 377
Amylase isoenzyme in hemodialysis (abst) 193
Amyloidosis
dialysis, tissular distribution (abst) 1416
fibrillary glomerulonephritis 781
hemodialysis (abst) 227
spohdylarthropathies of hemodialysis (abst) 1399
fluid partition (abst) 423
Analgesic abuse, interstitial nephritis 1416
Anaphylactic reaction in dialysis (abst) 243
Anaphylactoid purpura nephritis (abst) 192
Anatomy
nephron S-25
of Ang II site S-2
associated disease in chronic HD (abst) 341
bone cell response to PTH and vitamin D3 736
bone uptake, PTH (abst) 354
cardiac abnormalities in HD (abst) 238
chelation, deferoxamine 986
Subject Index: Vol. 31 xli
Ancillary conductance pathways (abst) 168
Androgen therapy in hemodialysis 100
Anemia
Al induced in hemodialysis (abst) 225
in ESRD, correction of (abst) 198
of ESRD l05
Angioplasty in hypertension (abst) 869
Angiotensin
ANF (abst) 286
binding sites correlate with ANP (abst) 278
CEI, All (abstO 390
functional receptors on PCT (abst) 291
mRNA expression in ontogeny (abst) 268
Angiotensin converting enzyme
inhibition, artery stenosis (abst) 299
acute tubular necrosis S-143
Ang II in chronic renal failure S-112
normal kidney S-104
renal disease S-l02
Angiotensin converting enzyme inhibitor
enalapril, enalaprilat in renal insufficiency S-l 17
not alike (abst) 307
Angiotensin I
and II on glomerular function (abst) 280
converting enzyme and kinin 744
converting enzyme and neutral endopeptidase S-45
Angiotensin II
binding studies in cirrhotic rats (abst) 291Ca + activated Cl conductance (abst) 282
captopril administration (abst) 262
chronic partial ureteral obstruction (abst) 421
control of renal renin release S-89
converting enzyme, reduction of proteinuria
(abst) 1044
cytosolic pH (abst) 271
dietary protein, vascular reactivity (abst) 425
dihydropyridine calcium antagonist felodipine
(abst) 1049
heart failure, renal function and S-220
hemodynamics and ultrafiltration coefficient (abst) .... 427
interlobular arterial resistance 1291
intracapillary volume (abst) 276
isolated glomeruli and cultured glomerular cells S-74
mechanism of decreased vascular response,
hypertension 906
modulates glomerular All receptors (abst) 287
periarterial pathway for renin s-S 1
PGE2 synthesis (abst) 285
proximal tubular fluid reabsorption, Ca, lipoxygenase
(abst) 279
reabsorption dependent on Ca and lipoxygenase
(abst) 279
saline loading (abst) 419
secretagogue of ANP (abst) 292
thromboxane A2, ureteral occlusion (abst) 394
tubular effects S-81
ultrafiltration coefficient (abst) 426
Anion
current, NaC1 transport (abst) 438
exchangers, cDNAs encoding (abst) 159
organic, cyst formation (abst) 159
Anionic
proteins, tubular uptake of proteins (abst) 449
sites in cspillaries 52
surface charges (abst) 159
Anoxia
change in energy reserves during ischemia 1239
Antagonism, hydrochlorothiazide 1097
Antagonists
Ca in DahI 941
Anti-GBM nephritis
terminal complement pathway (abst) 321
Anti-glomerular basement membrane
antibody, intrarenal hemodynamic alterations 8
human, induces glomerulonephritis in sheep 25
epitopic specificity, antisera (abst) 322
Anti-viral factor in dialysate (abst) 251
Antibody
anti-a-, immune complexes in children, IgAN, HS
purpura 1132
anti-tubular basement, interstitial nephritis (abst) 316
anto-interleukin 2 receptor (abst) 324
distribution of renin and angiotensin S-4
Fc, uptake of macromolecules (abst) 327
glomerular extracellular matrices (abst) 326
identification of monoclonal (abst) 327
membranous nephritis, glycoprotein (abst) 338
mesangial cell injury (abst) 333
monoclonal against laminin A chain and B chain (abst). 325
monoclonal, leukocyte analysis in
glomerulonephritis 964
PG production mechanism (abst) 315
RNA polymerase I (abst) 331
solid phase Clq, membranous glomerulophritis
(abst) 331
specificity to streptococcus mutans (abst) 315
trypanosomiasis-related glomerulonephritis (abst) ... . 1047
Anticoagulation in hemodialysis (abst) 240
Antidiuretic hormone
cellular response (abst) 447
effect on collecting duct 530
MTAL volume regulation (abst) 446
receptor to vasopressin and other hormones 512
stimulated water reabsorption (abst) 450
TAL and internephron heterogeneity to urine
concentration 549
urinary acidification (abst) 405
urine concentrating mechanism 549
Antidiuretic
5K&F 101926 (abst) 267
Antigen
anti-GP600 of Heymann nephritis (abst)





failure to induce IgA nephropathy (abst) 1046
fibronectin binding (abst) 316
Goodpasture target in GBM (abst) 340
HLA-A, B, DR in Greek idiopathic GN patients
(abst) 863
interleukin 1, interferon gamma, endotoxin (abst) 322
major histocompatibility complex, murine kidney
(abst) 463
monoclonal anti-DNA antibodies (abst) 326
proteinuria in GN (abst) 333
recognition complex, T cell activation (abst) 469
target for immune deposits (abst) 329
target in human anti-tubular basement membrane
nephritis 800
tubular damage in tubulointerstitial nephritis
(abst) 335
xlii Subject Index: Vol. 31
Antihypertensive
mechanism of hydrochiorothiazide response,
indomethacin 1097
therapy, DAHL rats 718
therapy, NSN (abst) 379
Antimycin A, ATP (abst) 162
Antiporter
Na-H activity and HCO3 reabsorption (abst) 418
Na/H mediates bicarbonate absorption (abst) 414
Antithymocyte serum, CyA (abst) 455
Apical chloride channels, colon (abst) 435
Apical membrane
cAMP(abst) 181
Cl/base exchange (abst) 428
Aplastic bone disease (abst) 349
Apoferritin immune complex GN (abst) 319
Aprotinin, vasopressin 1092
Arachidonic acid




indomethacin blocks rise (abst) 201
Arginine vasopressin
ANF on Ca in vascular smooth muscle cells (abst)... 309
cAMP, Ca-calmodulin (abst) 289
dimethyl sulfoxide, water flow (abst) 292
Na-K-ATPase in CCD (abst) 289
removal stimulates secretion (abst) 258
trifluperazine and napthalene-sulfonamide (abst) 284
Arterial resistance, interlobular 1291
Arterioles, a-adrenoceptor (abst) 422
Artery
contraction (abst) 420
evaluation of renal, DSA (abst) 867
renal, morphology of renin synthesis S-18
Ascending vasa recta, models 662
Ascites, transport (abst) 253
Aspirin, diabetic GN (abst) 194
Atherosclerosis, vascular disease 1153
percutaneous transluminal angioplasty (abst) 192
ATP
clathrin-coated vesicle proton pump (abst) 183
content in proximal cells (abst) 170
H202 injury (abst) 159
ATPase
adriamycin mediated by oxygen free radical species
(abst) 1045
Ca2, Mg2 dependent (abst) 342
characterization of H— (abst) 414
Cl channel inhibitors and diuretics on (abst) 409
H, immunocytochemical localization of (abst) 167
H, structural heterogeneity (abst) 169
mitochondria-rich cell plasma (abst) 162
Na-K activity, glucocorticoid receptors (abst) 165
vanadate sensitive activity (abst) 413
Atrial natriuretic factor
ADPKD (abst) 295
ammonucleoside-induced NS (abst) 272
cirrhosis with ascites, nephrotic syndrome (abst) 273
cisplatin nephrotoxicity (abst) 365
cytosolic free Ca (abst) 258
dose-response relationship (abst) 288
experimcntal nephrosis (abst) 283
failure to induce natriuresis (abst) 264
Goldblatt hypertension (abst) 295
hAND 102—126 in normals (abst) 270
ischemic ARF (abst) 371
Na excretion, tachycardia (abst) 280
Na retention, heart failure (abst) 291
natriuretic at physiologic concentrations (abst) 293
nucleotide accumulation in CCTC (abst) 281
receptors and response, low salt diet (abst) 257
renal, cardiovascular, endocrine actions (abst) 286
renin-angiotensin system (abst) 286
saline infusion in hypertensive, normotensive
(abst) 282
various diuretics on isolated nephron segments 946
vasopressin in pulmonary edema (abst) 195
ventricular immunoreactive (abst) 268
Atrial natriuretic peptide
adenine nucleotide (abst) 397
aldosterone response to hypervolemia (abst) 274
angiotensin 11 a secretagogue (abst) 292
arginine vasopressin (abst) 274
artificial heart implantation (abst) 202
binding sites correlate with All (abst) 278
cardiac changes obscure renal effects of (abst) 274
CEI and renal function in cardiac failure S-216
cGMP metabolism (abst) 397
characteristics in renal diseases (abst) 278
cirrhosis (abst) 262
concentrations, effect on release of renin (abst) 263
coronary sinus (abst) 261
CRF, cardiac denervation (abst) 284
dehydration 760
determination in microliter samples (abst) 259
dietary salt (abst) 288
essential hypertension (abst) 296
glomerular binding (abst) 198
inhibition of Ca2 ATPase activity (abst) 266
inositol trisphosphate (abst) 277
mechanism of natriuretic action (abst) 1049
mechanism of renal natriuretic action (abst) 273
metabolism by membranes and tubules (abst) 271
myocardial infarction, Na (abst) 279
Na reabsorption (abst) 290
natriuresis after, in sodium restriction (abst) 1049
not dominant in natriuresis (abst) 270
papillary collecting duct transport (abst) 430
PGE2, 6-keto-PGF1a production (abst) 272
PTH (abst) 400
receptors along the nephron (abst) 262
renal effects (abst) 265
renal function and BP (abst) 391
specific receptors in medullar collecting duct (abst). . . . 271
thromboxane-induced vasoconstriction (abst) 277
vasa recta blood flow (abst) 280
vasoactive hormones in nephrotic syndrome 1373
volume expansion and contraction in normal men
(abst) 285
Atrial peptide
physiological regulator of pressures (abst) 260
Atriopeptin
resets tubuloglomerular feedback (abst)
Atriopeptin III, cGMP, renin (abst)
Attitudes towards kidney donation (abst)
Auto-immune glomerulonephritis
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against granulocyte cytoplasm (abst) 337
renal failure (abst) 320
Autologous immune complex nephritis
hybridoma model (abst) 313
Autonomic insufficiency in BP (abst) 297
Autoradiography, angiotensin receptor S-40
Autosomal dominant inheritance, Mg 1140
Autosomal dominant PKD
132 microglobulin in 85
cyst formation and growth 1145
renal structure and concentrating ability (abst) 197




B6 deficiency (abst) 248
cyclosporine induced (abst) 463
prerenal, GFR (abst) 293
Al adensine receptors
chloride transport (abst) 274
Baboon GFR (abst) 380
Bacteria, Tamm-Horsfall protein 77
Baroreflexes, Ang II in stenosis
Basolateral membrane
adrenergic receptor stimulation (abst)
non-selective cation channel (abst).
Benxyl alcohol, MDCK cells (abst)
Benzodiaxzepine binding site (abst)
Berliner tribute
Beta adrenergic blockade (abst)
Beta adrenoceptor
vasodilation (abst)
Beta receptor, cAMP (abst)
Beta 2 microglobulin
adsorption to highflux membranes (abst)




uremics in hemodialysis (abst)
Beta-adrenoceptor
in sheep (abst)
peritoneal dialysis patients (abst)
vasodilation, norepinephrine (abst)
Bicarbonate
acidification in PCT inhibited during alkalosis (abst)
amiloride (abst)
ammonia transport (abst)
chronic load, K, Cl or KCL depletion (abst)
concentration (abst) 405
generation, acetate metabolism during HD 1194
high, dialysate for repletion (abst) 240
metabolic acidosis in SHR (abst) 302
Na-H antiporter activity and, in post-hypercapnic
(abst) 418
Na/H antiporter mediates absorption (abst) 414
pHi regulation in S3 proximal tubule (abst) 412
phosphorus levels in hemodialysis (abst) 231
rapid high effeciency HD (abst) 235
sequential changes in during dialysis (abst) 236
transport (abst) 407
Binding properties, antibodies (abst) 326
Binding, C5a during hemodialysis 112
Biologic-HO dialysis machine (abst) 227
Blycolysis
DCCD in suspensions of nephron segments (abst) 403
Body fluid compartments (abst) 283
Bone
aluminum
associated disease in HD (abst)
induced disease, PTH (abst)
trabecular vs. cortical in HD (abst)
cell metabolism, Al, PTH and vitamin D3
deferoxamine in Al-related disease 1326
lead toxification (abst) 196
223
343
marrow transplant, hypomagnesemia (abst)
microprobe determination of cell function (abst)
renal mass and reserve of vitamin D, hyperparathyroid-
ism 1174
Biopsy
calcium content and renal impairment in 246 93
fibrillary glomerulonephritis 781
fine needle aspiration, ultrasonically guided (abst) 462
probe renal disease (abst) 198
rejection in intra-operative (abst) 453
Bisphosphate, 2,6 fructose (abst) 401
Blood
active and inactive renin, ACE inhibition S-l84
coagulopathy in nephrotic children 772
flow measurement, cine computed tomography 1038
flow regulation, hypertonic urine formation 668
GFR, bradykinin antagonist infusion (abst) 419
HTLV-III in hemodialysis (abst) 227
immunoglobulin-secreting cells in, IgAN (abst) 338
indium-l 11-labeled white cell scan (abst) 468
ionized Ca in RD (abst) 346
lymphocytes and monocytes in peripheral (abst) 862
medullary flow 641
peripheral, mononuclear cell function, verapamil
(abst) 471
pressure, hypertension in renal transplant
recipients 1024
red cells, sodium lithium counter transport (abst) 190
split hydronephrotic kidney, angiotensin II S-64
transfusion, transplantation (abst) 455
442 transfusions, renal transplantation (abst) 459
166 tubings, C3a anaphylatoxin generation (abst) 1400
278 vasa recta flow, ANP (abst) 280
502 Blood flow
428 ACE inhibition and acute tubular necrosis S-l43
physiology of intrarenal renin-angiotensin system . . . . S-49
Blood pressure
ACE inhibition and renal disease S-102
ACE inhibition in hypertensives 815
ANP effect on renal function (abst) 391
changes in bone marrow transplant (abst) 297
chronic renal failure progression (abst) 189
diabetic nephropathy 898
238 donor, recipient 1366
229 family history and hypertension (abst) 298
hemorrhagic reduction in ARF 725
175 K in elderly (abst) 311
197 lowering of arterial, diabetes S-123
425 Na nitroprusside reduced, hypertension (abst) 306
norepinephrine vs. angiotensin II S-193
412 regulation, K, norepinephrine, Ang II mediated 956
418 renal damage, CE! S-l68
408 renal function in insulin-dependent diabetes (abst) 207
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single channel fluctuations from (abst) 348
thyroparathyroidectomy modifies response to Al loading
Bowman's space, crecentic neph. (abst)
Bradykinin
Ca from intracellular tubular stores (abst)
inhibits transport-dependent 02 consumption (abst).
MCDK cells (abst)
prostaglandin formation, renal function, renin (abst)...
Brain
catecholamines, P depletion (abst)
damage, symptomatic hyponatremia (abst)
dehydration, hyponatremia (abst)




osmolarity influence on Na/H exchanger (abst) 406
Bumetanide and furosemide (abst) 213
C-PTH(35—84PTH), CRF (abst) 871
Cadium, PTH-adenylate cyclase (abst) 173
Calcitonin degradation (abst) 399
Calcitriol
clearance in CRF (abst) 350
production in SHR (abst) 362
synthesis by P (abst) 352
therapy in children (abst) 220
Calcium
absorption in cTAL, PTH stimulated 913
activated K channels in MTAL (abst) 431
adenosine signal transduction (abst) 259
adrenergic agonists increase (abst) 284
Al in hypercalcemia 766
antagonists and renin release (abst) 260
ATP-driven in BLMV (abst) 359
ATPase activity in RBC (abst) 236
ATPase in RBC in HD (abst) 236
AVP, ANF in vascular smooth muscle cells (abst) .. .. 309
binding protein, 28 kDa vitamin D 121
binding to membranes, aminoglycoside,
phosphoinositide




channel blocking, cyclosporine nephrotoxicity (abst).
channel in UMR- 106 cells (abst)
citrate as a phosphate binder (abst)
C1 conductance, angiotensin II (abst)
CO3 for Al-GELS, aplastic bone disease (abst)
cytosolic free Ca2 concentration, PAF in mesangial
(abst) 161
cytosolic free levels (abst) 172, 258, 361
cytosolic in single proximal tubule cells (abst) 167
diet in hypertension (abst) 298
dihydropyridine antagonist felodipine, Ang II (abst) .. 1049
early rise in cytosolic free (abst) 180
excretion, KHCO3 (abst) 353
excretion, Mg (abst) 357
fluctuations modulate permeability (abst) 449
fluxes in enterocytes (abst) 345
free, FURA 2 measurements (abst) 350
FURA-2 measurements in hypertension (abst) 302
gender lnd acidification in stone former (abst) 347
gentamicin nephrotoxicity, PTH (abst) 366
glucose modulate renal responses (abst) 395
923 hypercalcemia and malignancy 142
333 hypertension, PGE2 production (abst) 292
influx of SHR isolated enterocytes (abst) 308
282 intake, salt in hypertension (abst) 308
293 intracellular, essential hypertension (abst) 869
178 ionized, regulation by vitamin D3 (abst) 360
426 lipid dependent kinase following nephron loss (abst)... 399
lipoxygenase, All (abst) 279
342 Mg2 dependent ATPase (abst) 342
190 Na ,K-ATPase inhibition (abst) 295
219 nephrolithiasis, urinary glycosaminoglycans (abst) 864
223 newborn handling 1181
nitrendipine effect on gentamicin nephrotoxicity (abst). 369
oxalate and carbonate supersaturations in pregnancy
(abst) 209
oxalate crystal growth inhibition, nephrocalcin (abst) .. 361
oxalate crystal growth, pregnancy (abst) 359
oxygen free radical damage, marine lipids (abst) 370
platelet-derived growth factor modulates (abst) 175
prostaglandin (abst) 267
proton fluxes from calvariae (abst) 361
PTH activated, regulation by phorbol ester (abst) 351
PTH stimulation of cytosolic (abst) 346
regulation of vitamin D3 (abst) 352
relation between content, and renal impairment 93
response of isolated Dahl kidney to antagonists 941
sodium exchange (abst) 345
stone former, uric acid (abst) 215
stone former, vitamin D3 (abst) 1416
supplementation on blood lead and BP (abst) 209
sytosolic Ca2 in LLC-PKI, exogenous nucleotide
(abst) 185
therapeutic agent for renal osteodystrophy (abst) 344
transport in vitamin D-deprived SHR (abst) 350
uptake in FIgC12 injured tubules (abst) 365
uptake is early renal hypertrophy (abst) 399
vasopressin induced increases (abst) 449
zinc nutritional status (abst) 358
59 25,26—dihydroxyvitamin D3 (abst) 362
298 Calmodulin antagoinists (abst) 347
282 cAMP
795 ANP inhibits aldosterone secretion (abst) 260
289 AVP, arachidonic acid, LLC-PKI cell (abst) 276
454 binding proteins in medullary collecting tubule (abst) .. 270
188 Ca in cultured epithelia (abst) 162
239 Ca induced prostacyclin (abst) 264
282 dependent protein kinase, apical membrane (abst) 181
349 effect on phosphate transport, 32P in ATP (abst) 184
forskolin and vasopressin on urinary bladder (abst).... 448
lithium, Ns mediates (abst) 258
mediated beta receptor response (abst) 281
mediated protein dephosphorylation (abst) 177
reconstitution of protein kinase, Na-H exchanger
(abst) 186
regulation in renal microvessels (abst) 163
vasopressin signalling 521
vasopressin-sensitive nephron segments 1065
Cancer
gentamicin and cisplatinum, renal function (abst) 215
hypercalcemia of malignancy 142
interleukin-2 therapy (abst) 224
regression of metastatic renal (abst) 340
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CAPD
algae peritonitis misdiagnosed as fungal (abst) 256
cellular immunity (abst) 862
center city hospital (abst) 249
changes in peritoneal solute transport (abst) 248
clinical evaluation of program (abst) 861
CPK heart isoenzyme (abst) 871
deferoxamine for aluminum chelation 986
enhanced neuropsychological function (abst) 253
Greece (abst) 861
HD effect on renal patient cellular immunity (abst). . . . 862
hepatis B vaccine (abst) 249
hepatitis B vaccine evaluation (abst) 249
iatrogenic complications of (abst) 861
kinetics of water and electrolytes in dialysate (abst) . . . 866
left ventricular funtion, intra-abdominal pressure
(abst) 248
long term survivors (abst) 257
lymphatic absorption in (abst) 252
management of multiple enteric organism peritonitis
(abst) 254
media enrichment of infected bags (abst) 255
omega-3 polyunsaturated fatty acids (abst) 255, 1050
peritoneal membrane, ultrafiltration (abst) 866
peritonitis rate by UV-XD (abst) 256
peritonitis, ticarcillin-clavulanic acid (abst) 250
PTH, vitamin D3 (abst) 354
secondary hyperparathyroidism, calcitriol, Ca and
PTH 795
T-lymphocyte transformation (abst) 862
transplantation after prolonged dialysis 981
tunnel infection management (abst) 869
vancomycin in (abst) 255
l,25(OH)2D3 synthesis by peritoneal macrophages
(abst) 249
Capillary barrier, proteinuria (abst) 314
Capillary solute flux (abst) 427
Captopril
ACE inhibition (abst) 333
ACE inhibitors not alike (abst) 307
acute tubular necrosis S-143
administration on vascular All (abst) 262
bradykinin, prostanoid production (abst) 275
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